Jade Biosciences, Inc. (NASDAQ:JBIO) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $20.80.

Several equities research analysts have weighed in on JBIO shares. BTIG Research started coverage on Jade Biosciences in a research report on Thursday, October 9th. They issued a “buy” rating and a $28.00 target price on the stock. Guggenheim increased their price objective on shares of Jade Biosciences from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Jade Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright started coverage on Jade Biosciences in a report on Wednesday, January 7th. They set a “buy” rating and a $25.00 price target on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc bought a new stake in shares of Jade Biosciences during the second quarter valued at about $29,000. Russell Investments Group Ltd. acquired a new position in Jade Biosciences during the 2nd quarter valued at about $31,000. BNP Paribas Financial Markets bought a new stake in shares of Jade Biosciences during the 2nd quarter worth about $32,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Jade Biosciences in the 2nd quarter worth approximately $33,000. Finally, New York State Common Retirement Fund lifted its stake in shares of Jade Biosciences by 4,180.3% in the 3rd quarter. New York State Common Retirement Fund now owns 5,222 shares of the company’s stock worth $45,000 after acquiring an additional 5,100 shares during the period.

Jade Biosciences Stock Up 4.5%

Shares of NASDAQ JBIO opened at $15.94 on Friday. The firm’s 50-day moving average price is $14.00 and its two-hundred day moving average price is $10.43. Jade Biosciences has a 52-week low of $6.57 and a 52-week high of $100.10. The stock has a market capitalization of $786.00 million, a P/E ratio of -1.43 and a beta of 1.02.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.